Full Press Release Details
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick
to its Board of Directors
Ms. FitzPatrick, an internationally recognized corporate affairs
executive, brings extensive healthcare consumer engagement,
marketing and public relations expertise to the Company's
SOUTH SAN FRANCISCO, Calif. July 22, 2021
VistaGen Therapeutics,
biopharmaceutical company committed to developing a new generation
of medicines with the potential to go beyond the current standard
of care for anxiety, depression and other central nervous system
( CNS ) disorders, today announced the appointment of
Maggie FitzPatrick to its Board of Directors ( Board ),
replacing Dr. Brian J. Underdown who recently retired from the
is a highly-regarded public affairs strategist with extensive
experience developing and executing multiple high impact
customer-focused marketing communications initiatives for some of
the world's largest and most successful companies, including
Johnson & Johnson and Cigna, said Shawn Singh, Chief
Executive Officer of VistaGen. Her expertise in positioning
companies and products through public relations, marketing and
digital media campaigns will be valuable both before and after
commercial launch of our product candidates. We are excited to have
Maggie on our Board as we continue to progress through key stages
of our corporate growth with a steadfast commitment to improving
mental health and well-being for individuals all around the
FitzPatrick is a globally recognized corporate affairs executive
who has been honored with several prestigious awards, including the
Washington Business Journal's C-Suite Executive of the Year
Class (2019), PR Week's Top 50 Most Powerful People in PR
(2015) and PR Week's Hall of Femme (2019). Recently, she
served as a member of the Exelon Corporation executive committee.
At Exelon, she led communications, customer engagement, digital and
crisis reputation management and philanthropy for the Fortune 100
Company. Prior to Exelon, Maggie served as Global Chief
Communications Officer and led public affairs at Johnson &
Johnson, the world's largest and most broadly-based healthcare
company. She directed a global team of more than 425 professionals
and oversaw the modernization and transformation of Johnson &
Johnson's global public affairs, reputation management and digital
content programs. She and her team implemented a customer-focused
strategy to strengthen engagement initiatives across the
company's 265 operating companies, across sixty countries.
Prior to Johnson & Johnson, Maggie served as Global Chief
Communication Officer and President of the Foundation at Cigna,
where she led a corporate re-branding effort and directed marketing
communications for the company's global expansion. Previous
to that, Maggie was Executive Vice President at APCO Worldwide, a
global public affairs and strategic communications consultancy. In
this role she counseled executives on major global reputation
efforts for notable industry leaders such as eBay and United
Airlines, among others. Maggie also serves on the board of the
Southeast Tennis and Learning Center in Washington, D.C. In 2020,
she was appointed by DC Mayor Muriel Bowser to serve as a
Commissioner on the DC Commission on the Arts and
FitzPatrick holds a B.A. in English and Policy Studies from
Syracuse University, and an M.A. in Public Policy from The George
Washington University. In 2018, she completed the Harvard Business
School program for corporate directors.
Saxe, Chairman of the Board, added, On behalf of the Company
and its stockholders, I would like to extend a heartfelt thank you
to Dr. Underdown for his long service to our Board and for his
contributions in helping grow the company. We wish him the very
best in his retirement and all of his future endeavors. I would
also like to welcome Maggie to the VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to
developing and commercializing innovative medicines with the
potential to go beyond the current standard of care for anxiety,
depression, and other CNS disorders. Each of VistaGen's three drug
candidates has a differentiated potential mechanism of action, has
been well-tolerated in all clinical studies to date, and has
therapeutic potential in multiple CNS markets. For more
information, please visit www.VistaGen.com
and connect with VistaGen
Forward Looking Statements
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as may, could,
expect, project, outlook,
strategy, intend, plan,
strive, goal, continue,
likely, will, would and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by us and our management, are
inherently uncertain. Our actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference are fully
discussed in the section entitled "Risk Factors" in our most recent
Annual Report on Form 10-K for the fiscal year ended March 31,
2021, as well as discussions of potential risks, uncertainties, and
other important factors in our other filings with the U.S.
Securities and Exchange Commission (SEC). Our SEC filings are
available on the SEC's website at www.sec.gov. You should not
place undue reliance on these forward-looking statements, which
apply only as of the date of this press release and should not be
relied upon as representing our views as of any subsequent date. We